Carrot's InSightVR Acquisition Maps a New Blueprint for Ophthalmic Care

BROOKLYN, NY – October 09, 2026

In the rapidly consolidating world of medical technology, the most lucrative innovations are rarely the ones that invent entirely new procedures. Instead, they are the systems that seamlessly connect existing operational silos. Carrot, the Brooklyn-based company formerly known as Virtual Field, has just executed a textbook example of this strategy.

Today, the virtual reality diagnostic platform announced an agreement to acquire GreenMan Vision, Inc., the developer behind the intraocular lens (IOL) simulation platform InSightVR. While the financial terms of the deal remain undisclosed, the strategic implications are glaringly apparent. By bringing pre-surgical visual simulation under the same umbrella as its dominant diagnostic testing platform, Carrot is moving aggressively from the realm of clinical measurement into the high-margin, elective surgical decision workflow.

For leaders tracking the industrialization of healthcare, this acquisition is more than a hardware play. It is a calculated vertical integration that bridges the traditional divide between referring optometrists and operating ophthalmologists, fundamentally altering how patients consume—and purchase—surgical outcomes.

From Diagnosis to Decision: A High-Margin Pipeline

Since its founding in 2018, Carrot has quietly built a formidable footprint in ophthalmic diagnostics. Its VR headsets are currently deployed in more than 2,500 clinics, having processed over 6 million eye exams. Historically, the company’s core utility has been replacing the dreaded, time-consuming visual field test—a staple for glaucoma monitoring—with a faster, AI-assisted virtual alternative.

However, diagnostics, while essential, are often lower-margin operational necessities. The real financial engine in eye care is elective surgery, specifically the millions of cataract procedures performed annually in the United States.

Cataract surgery represents a critical juncture where clinical necessity meets consumer choice. Patients must decide which intraocular lens will replace their clouded natural lens. Standard monofocal lenses are typically covered by insurance, but "premium" advanced-technology lenses—which correct astigmatism (toric) or offer multifocal and extended-depth-of-focus capabilities—require significant out-of-pocket investments.

Until now, this $3,000-to-$5,000 consumer choice has largely been driven by rudimentary tools: verbal counseling, plastic eye models, and glossy brochures. Carrot’s acquisition of InSightVR changes that dynamic entirely. By integrating GreenMan’s software, Carrot can now offer a continuous digital thread from the initial diagnostic exam in an optometry clinic directly to the surgical consultation in an ophthalmology practice. As one health-tech analyst noted privately, controlling the educational touchpoint right before a high-value surgical decision is one of the most coveted positions in medical technology.

Closing the Premium Lens Expectation Gap

The clinical and business problem that InSightVR solves is known in the industry as the "expectation gap." Advanced-technology lenses offer life-changing independence from glasses, but they come with optical tradeoffs, such as potential glare or halos around lights at night.

GreenMan Vision was founded by cataract surgeons Michael Greenwood, MD, and Brandon Baartman, MD, of Vance Thompson Vision, specifically to address this friction. Using a patient’s unique biometry, InSightVR places them in immersive, everyday environments—like reading a book or driving at night—allowing them to virtually test-drive different lens options before an incision is ever made.

“We built InSightVR for our own patients, and we held it to one standard: it could never overpromise an outcome,” said Dr. Greenwood in the acquisition announcement. Dr. Baartman echoed the sentiment, noting, “When patients can see the tradeoffs for themselves, the decision becomes theirs.”

The business case for this immersive education is staggering. According to a 2026 retrospective study of 609 patients cited by the companies, 57.1% of patients who used InSightVR opted for an advanced-technology lens, compared to just 28.4% of those who received standard counseling. Doubling the conversion rate of premium lenses without increasing clinical headcount is a compelling proposition for any surgical practice. Furthermore, the data suggests that 90% of surveyed patients reported their post-operative vision aligned with the VR simulation, mitigating the risk of buyer's remorse.

Navigating the Regulatory and Operational Reality

Despite the promising conversion metrics, integrating virtual simulation into surgical planning introduces complex regulatory and liability guardrails that healthcare administrators must navigate carefully.

Software that models post-surgical outcomes based on patient biometry typically falls under the FDA’s purview as Software as a Medical Device (SaMD). As algorithms increasingly influence clinical management and patient choices, the regulatory scrutiny regarding their accuracy and validation intensifies.

Furthermore, there is the issue of patient liability. If a patient pays out-of-pocket for a premium multifocal lens based on a VR simulation, but their real-world neuroadaptation fails to resolve post-operative halos, who bears the responsibility? The integration of InSightVR will require clinics to adopt rigorous informed consent protocols. The simulation must be explicitly framed as a highly educated prediction rather than a guaranteed clinical outcome. The surgeon ultimately remains responsible for the surgical plan, meaning the technology must serve as an educational aid rather than a definitive medical promise.

From a corporate structure standpoint, keeping the original InSightVR team intact is a shrewd move by Carrot. “Our customers will keep the same InSightVR team and the hands-on training and support they rely on,” stated Matt Larson, CEO of GreenMan. “What will change is scale. With Carrot, InSightVR will get in front of more surgeons and more patients than we could ever reach alone.”

The Immersive Clinic: VR's Shift to Standard Care

The Carrot and GreenMan merger is indicative of a broader transformation in clinical operations. Virtual reality is rapidly shedding its reputation as a cumbersome novelty, evolving instead into a multi-functional ecosystem capable of solving acute operational bottlenecks.

Competitors like Heru and Olleyes have also made significant strides in VR perimetry and diagnostics. However, Carrot’s expansion into surgical simulation differentiates its platform, transforming the headset from a pure diagnostic tool into a revenue-generating patient counseling center.

For practice administrators, the operational math is highly attractive. Traditional visual field testing requires dedicated dark rooms and constant technician supervision. VR headsets eliminate the need for specialized real estate and leverage AI/ML automation to free up staff. By stacking IOL simulation onto the same hardware, clinics can maximize the return on their capital equipment investments while simultaneously addressing the chronic staffing shortages plaguing the healthcare sector.

“When we became Carrot, we said we’d be defined by what we enable, not just what we measure,” said Jeremy Barlow, CEO of Carrot. “For years, Carrot has shown doctors how their patients see. Soon, we’ll be able to show patients how they could see. That’s life-changing.”

As the medical sector continues to grapple with the demands of an aging population and constrained resources, technologies that can simultaneously improve clinical workflows and drive high-margin revenue will dictate the future of the industry. Carrot's acquisition of GreenMan Vision is not merely an expansion of a product line; it is a strategic blueprint for how modern medical technology companies will capture value across the entire continuum of patient care.